Mumbai-based specialty chemicals and pharmaceutical company manufacturing/importing API intermediates and bulk drugs, and trading finished formulations and branded generics
Price
Market Cap
Sector
Commodities
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 10 | 10 | 10 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 10 | 13 | 20 | 77 | 88 | 107 | 116 | 131 |
| Borrowings | 21 | 30 | 31 | 34 | 105 | 171 | 219 | 285 |
| Other Liabilities | 18 | 47 | 77 | 97 | 67 | 100 | 148 | 202 |
| Total Liabilities | 58 | 99 | 138 | 232 | 283 | 402 | 507 | 642 |
| AssetsFixed Assets | 6 | 6 | 6 | 20 | 26 | 24 | 53 | 104 |
| CWIP | 0 | 0 | 1 | 0 | 2 | 6 | 28 | 3 |
| Investments | 0 | 0 | 0 | 12 | 14 | 30 | 2 | 0 |
| Other Assets | 53 | 93 | 131 | 200 | 242 | 342 | 424 | 534 |
| Total Assets | 58 | 99 | 138 | 232 | 283 | 402 | 507 | 642 |
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 1 | 3 | -4 | -29 | 6 | 35 | -2 |
| Cash from Investing | -3 | -1 | -1 | -26 | -5 | -20 | -78 |
| Cash from Financing | 0 | -1 | 4 | 66 | -12 | -14 | 79 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — |
| Free Cash Flow | -4 | 1 | -5 | -43 | 2 | 30 | -51 |
| FCF Margin | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (33.8×) and current (43.4×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 33.3% growth and a 34× exit, ₹37 only delivers your return if you pay ₹58. The price is currently baking in 23% growth.
EPS grows 33.3%/yr for 5 years, then fades to 6% over 2, exits at 34×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 33.3% | 1.13 |
| FY28 | 33.3% | 1.51 |
| FY29 | 33.3% | 2.01 |
| FY30 | 33.3% | 2.68 |
| FY31 | 33.3% | 3.58 |
| FY32 | 19.6% ·fade | 4.28 |
| FY33 | 6.0% ·fade | 4.54 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.